Clinical Policy: Niraparib/Abiraterone Acetate (Akeega)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.645 alerts
Get alerted when Policy CP.PHAR.645 changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization for niraparib/abiraterone acetate (Akeega) in adults with specified metastatic prostate cancer indications across commercial, HIM/ICHRA, and Medicaid lines of business in Nevada.
The policy removed coverage for the previously described off-label use involving disease progression despite bilateral orchiectomy or other androgen deprivation therapy.
The initial approval duration was extended from 6 months to 12 months for Medicaid and HIM members.
A new indication for BRCA2-mutated metastatic castration-sensitive prostate cancer was added.
The ICHRA line of business was added to the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.